Varuby

RSS

Withdrawn

This medicine's authorisation has been withdrawn

rolapitant
MedicineHumanWithdrawn

Czech is available via eTranslation, the European Commission's machine translation service.

Translate to Czech | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 23 January 2020 the European Commission withdrew the marketing authorisation for Varuby (rolapitant) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Tesaro Bio Netherlands B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Varuby was granted marketing authorisation in the EU on 20 April 2017 for the prevention of nausea and vomiting. The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for Varuby is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (726.36 KB - PDF)

Zobrazit

español (ES) (633.54 KB - PDF)

Zobrazit

čeština (CS) (705.18 KB - PDF)

Zobrazit

dansk (DA) (632.71 KB - PDF)

Zobrazit

Deutsch (DE) (634.3 KB - PDF)

Zobrazit

eesti (ET) (630.21 KB - PDF)

Zobrazit

ελληνικά (EL) (730.25 KB - PDF)

Zobrazit

français (FR) (633.57 KB - PDF)

Zobrazit

hrvatski (HR) (681.74 KB - PDF)

Zobrazit

italiano (IT) (632.87 KB - PDF)

Zobrazit

latviešu (LV) (687.32 KB - PDF)

Zobrazit

lietuvių (LT) (657.39 KB - PDF)

Zobrazit

magyar (HU) (697.73 KB - PDF)

Zobrazit

Malti (MT) (800.33 KB - PDF)

Zobrazit

Nederlands (NL) (632.83 KB - PDF)

Zobrazit

polski (PL) (705.44 KB - PDF)

Zobrazit

português (PT) (633.6 KB - PDF)

Zobrazit

română (RO) (655.62 KB - PDF)

Zobrazit

slovenčina (SK) (703.81 KB - PDF)

Zobrazit

slovenščina (SL) (697.48 KB - PDF)

Zobrazit

suomi (FI) (632.75 KB - PDF)

Zobrazit

svenska (SV) (631.56 KB - PDF)

Zobrazit

Product information

български (BG) (1.63 MB - PDF)

Zobrazit

español (ES) (986.93 KB - PDF)

Zobrazit

čeština (CS) (1.39 MB - PDF)

Zobrazit

dansk (DA) (892.42 KB - PDF)

Zobrazit

Deutsch (DE) (914.89 KB - PDF)

Zobrazit

eesti (ET) (881.8 KB - PDF)

Zobrazit

ελληνικά (EL) (1.79 MB - PDF)

Zobrazit

français (FR) (901.62 KB - PDF)

Zobrazit

hrvatski (HR) (1.12 MB - PDF)

Zobrazit

italiano (IT) (902.93 KB - PDF)

Zobrazit

latviešu (LV) (1.41 MB - PDF)

Zobrazit

lietuvių (LT) (953.91 KB - PDF)

Zobrazit

magyar (HU) (1.39 MB - PDF)

Zobrazit

Malti (MT) (1.48 MB - PDF)

Zobrazit

Nederlands (NL) (891.74 KB - PDF)

Zobrazit

polski (PL) (1.44 MB - PDF)

Zobrazit

português (PT) (890.31 KB - PDF)

Zobrazit

română (RO) (977.61 KB - PDF)

Zobrazit

slovenčina (SK) (1.4 MB - PDF)

Zobrazit

slovenščina (SL) (1.36 MB - PDF)

Zobrazit

suomi (FI) (903 KB - PDF)

Zobrazit

svenska (SV) (892.21 KB - PDF)

Zobrazit

Íslenska (IS) (898.84 KB - PDF)

Zobrazit

norsk (NO) (1023.77 KB - PDF)

Zobrazit
Latest procedure affecting product information:T/0015
11/03/2019
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (618.68 KB - PDF)

Zobrazit

español (ES) (577.08 KB - PDF)

Zobrazit

čeština (CS) (600.04 KB - PDF)

Zobrazit

dansk (DA) (574.19 KB - PDF)

Zobrazit

Deutsch (DE) (576.81 KB - PDF)

Zobrazit

eesti (ET) (574 KB - PDF)

Zobrazit

ελληνικά (EL) (618.26 KB - PDF)

Zobrazit

français (FR) (573.96 KB - PDF)

Zobrazit

hrvatski (HR) (610.25 KB - PDF)

Zobrazit

italiano (IT) (573.83 KB - PDF)

Zobrazit

latviešu (LV) (607.89 KB - PDF)

Zobrazit

lietuvių (LT) (591.92 KB - PDF)

Zobrazit

magyar (HU) (599.13 KB - PDF)

Zobrazit

Malti (MT) (602.7 KB - PDF)

Zobrazit

Nederlands (NL) (573.91 KB - PDF)

Zobrazit

polski (PL) (597.52 KB - PDF)

Zobrazit

português (PT) (574.02 KB - PDF)

Zobrazit

română (RO) (590.38 KB - PDF)

Zobrazit

slovenčina (SK) (604.12 KB - PDF)

Zobrazit

slovenščina (SL) (595.43 KB - PDF)

Zobrazit

suomi (FI) (574.22 KB - PDF)

Zobrazit

svenska (SV) (573.78 KB - PDF)

Zobrazit

Íslenska (IS) (573.88 KB - PDF)

Zobrazit

norsk (NO) (588.52 KB - PDF)

Zobrazit

Product details

Name of medicine
Varuby
Active substance
rolapitant
International non-proprietary name (INN) or common name
rolapitant
Therapeutic area (MeSH)
  • Vomiting
  • Nausea
  • Cancer
Anatomical therapeutic chemical (ATC) code
A04AD

Pharmacotherapeutic group

Antiemetics and antinauseants

Therapeutic indication

Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
Varuby is given as part of combination therapy.

Authorisation details

EMA product number
EMEA/H/C/004196
Marketing authorisation holder
TESARO Bio Netherlands B.V.

Joop Geesinkweg 901
1114 AB Amsterdam-Duivendrecht
The Netherlands

Opinion adopted
22/02/2017
Marketing authorisation issued
19/04/2017
Revision
3

Assessment history

This page was last updated on

Share this page